TENAX THERAPEUTICS, INC. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Tenax's Phase 3 LEVEL trial of oral levosimendan (TNX-103) for PH-HFpEF failed its primary endpoint (6-minute walk distance improvement in overall population) but showed post-hoc benefits in sicker subgroups: 26.3-meter 6MWD improvement (p=0.0112), 49% NT-proBNP reduction (p<0.0001), and 3.5 mmHg RVSP reduction (p=0.0045) in prespecified analyses. Company paused LEVEL-2 enrollment to implement protocol amendment enriching for symptomatic patients and secured FDA Type C meeting. Cash position: $113.7M (9/30/26), runway through 2028; Q3 2026 net loss $16.7M; common shares outstanding increased to 45.5M from 9.3M at year-end 2025.
Why this rating
Failed primary endpoint threatens program viability; post-hoc enrichment strategy unproven and risky. Type C meeting is exploratory, not confirmatory. $113.7M cash vs. $23.8M market cap provides runway but major dilution occurred (4.9x share increase). Outcome materially affects company trajectory.
Tradability signal
SHORT
conviction 45/100 · expected -1.51% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (260 in this cell) moved +1.66% in the called direction over 4 hrs; shrunk for sample size that's a +1.51% edge. Price is down 3.4% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 4.3% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $1.79 ▲ 4.07% | at our read · unknown $1.72 | +10 min · unknown $1.71 ▼ 0.58% | +30 min · unknown $1.71 ▼ 0.58% | +1 hr · unknown $1.69 ▼ 2.03% | +4 hrs · unknown $1.60 ▼ 6.98% |
The stock had already moved -3.91% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.